201 related articles for article (PubMed ID: 12691626)
1. Low neuropsychologic performance among adult cancer survivors treated with chemotherapy.
Ferguson RJ; Ahles TA
Curr Neurol Neurosci Rep; 2003 May; 3(3):215-22. PubMed ID: 12691626
[TBL] [Abstract][Full Text] [Related]
2. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma.
Ahles TA; Saykin AJ; Furstenberg CT; Cole B; Mott LA; Skalla K; Whedon MB; Bivens S; Mitchell T; Greenberg ER; Silberfarb PM
J Clin Oncol; 2002 Jan; 20(2):485-93. PubMed ID: 11786578
[TBL] [Abstract][Full Text] [Related]
3. Clearing the air: a review of our current understanding of "chemo fog".
O'Farrell E; MacKenzie J; Collins B
Curr Oncol Rep; 2013 Jun; 15(3):260-9. PubMed ID: 23483375
[TBL] [Abstract][Full Text] [Related]
4. Cognitive Deficits in Breast Cancer Survivors After Chemotherapy and Hormonal Therapy.
Frank JS; Vance DE; Triebel KL; Meneses KM
J Neurosci Nurs; 2015 Dec; 47(6):302-12. PubMed ID: 26447567
[TBL] [Abstract][Full Text] [Related]
5. The impact of adjuvant therapy for breast cancer on cognitive function: current evidence and directions for research.
Rugo HS; Ahles T
Semin Oncol; 2003 Dec; 30(6):749-62. PubMed ID: 14663776
[TBL] [Abstract][Full Text] [Related]
6. Cognitive effects of standard-dose chemotherapy in patients with cancer.
Ahles TA; Saykin A
Cancer Invest; 2001; 19(8):812-20. PubMed ID: 11768035
[TBL] [Abstract][Full Text] [Related]
7. Cognitive speed of processing and functional declines in older cancer survivors: an analysis of data from the ACTIVE trial.
Kvale EA; Clay OJ; Ross-Meadows LA; McGee JS; Edwards JD; Unverzagt FW; Ritchie CS; Ball KK
Eur J Cancer Care (Engl); 2010 Jan; 19(1):110-7. PubMed ID: 19709169
[TBL] [Abstract][Full Text] [Related]
8. The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy.
Mehnert A; Scherwath A; Schirmer L; Schleimer B; Petersen C; Schulz-Kindermann F; Zander AR; Koch U
Patient Educ Couns; 2007 Apr; 66(1):108-18. PubMed ID: 17320337
[TBL] [Abstract][Full Text] [Related]
9. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients.
Schagen SB; Muller MJ; Boogerd W; Mellenbergh GJ; van Dam FS
J Natl Cancer Inst; 2006 Dec; 98(23):1742-5. PubMed ID: 17148777
[TBL] [Abstract][Full Text] [Related]
10. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial.
Wefel JS; Lenzi R; Theriault RL; Davis RN; Meyers CA
Cancer; 2004 Jun; 100(11):2292-9. PubMed ID: 15160331
[TBL] [Abstract][Full Text] [Related]
11. Information about chemotherapy-associated cognitive problems contributes to cognitive problems in cancer patients.
Schagen SB; Das E; Vermeulen I
Psychooncology; 2012 Oct; 21(10):1132-5. PubMed ID: 21769988
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning.
Deprez S; Amant F; Smeets A; Peeters R; Leemans A; Van Hecke W; Verhoeven JS; Christiaens MR; Vandenberghe J; Vandenbulcke M; Sunaert S
J Clin Oncol; 2012 Jan; 30(3):274-81. PubMed ID: 22184379
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-related cognitive dysfunction: current animal studies and future directions.
Seigers R; Schagen SB; Van Tellingen O; Dietrich J
Brain Imaging Behav; 2013 Dec; 7(4):453-9. PubMed ID: 23949877
[TBL] [Abstract][Full Text] [Related]
14. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen.
Castellon SA; Ganz PA; Bower JE; Petersen L; Abraham L; Greendale GA
J Clin Exp Neuropsychol; 2004 Oct; 26(7):955-69. PubMed ID: 15742545
[TBL] [Abstract][Full Text] [Related]
15. Meta-Analysis of the Effects of Neuropsychological Interventions on Cognitive Function in Non-Central Nervous System Cancer Survivors.
Zeng Y; Cheng AS; Chan CC
Integr Cancer Ther; 2016 Dec; 15(4):424-434. PubMed ID: 27151596
[TBL] [Abstract][Full Text] [Related]
16. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop.
Vardy J; Wefel JS; Ahles T; Tannock IF; Schagen SB
Ann Oncol; 2008 Apr; 19(4):623-9. PubMed ID: 17974553
[TBL] [Abstract][Full Text] [Related]
17. Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study.
Janelsins MC; Heckler CE; Peppone LJ; Kamen C; Mustian KM; Mohile SG; Magnuson A; Kleckner IR; Guido JJ; Young KL; Conlin AK; Weiselberg LR; Mitchell JW; Ambrosone CA; Ahles TA; Morrow GR
J Clin Oncol; 2017 Feb; 35(5):506-514. PubMed ID: 28029304
[TBL] [Abstract][Full Text] [Related]
18. Analysis of memory deficits following chemotherapy in breast cancer survivors: evidence from the doors and people test.
Prokasheva S; Faran Y; Cwikel J; Geffen DB
J Psychosoc Oncol; 2011; 29(5):499-514. PubMed ID: 21882931
[TBL] [Abstract][Full Text] [Related]
19. Neuropsychologic testing for chemotherapy-related cognitive impairment.
Myers JS
Adv Exp Med Biol; 2010; 678():55-69. PubMed ID: 20738007
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy and cognition: International cognition and cancer task force recommendations for harmonising preclinical research.
Winocur G; Johnston I; Castel H
Cancer Treat Rev; 2018 Sep; 69():72-83. PubMed ID: 29909223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
